Therefore, based on data from the oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN trial), we aimed to determine the target transferrin saturation levels to reduce cardiovascular events in patients with CKD treated for anemia with long-acting erythropoiesis-stimulating agents. This evidence concerns the gene TF and anemia.